Put yourself in my place
With the clinical regulatory landscape evolving across the UK and EU, should we be making the UK the go to place for Phase I clinical studies?
Feb 1, 2022
With the clinical regulatory landscape evolving across the UK and EU, should we be making the UK the go to place for Phase I clinical studies?
Global CDMO @skpharmteco has appointed David Lowndes as COO. With 38 years of experience & world-class results, David will lead the company’s Supply Chain, Quality, Regulatory Affairs, R&D, IT, & Operational Excellence functions through a period of growth: https://www.lifescienceintegrates.com/sk-pharmteco-appoints-david-lowndes-as-coo/
A great summary of the "Vive la difference" discussion from #PharmaIntegrates by Kathryn Simpson (Kathryn Simpson Consulting), featuring insights from panellists from @TakedaPharma Top Stream Coaching & Consulting, @Pfizer & @LabcorpDrugDev
https://www.linkedin.com/pulse/diversity-equity-inclusion-necessary-success-life-sciences-simpson%3FtrackingId=lArlbkF%252FTyK2xcz3DSziVQ%253D%253D/?trackingId=lArlbkF%2FTyK2xcz3DSziVQ%3D%3D
#LifeScience
With the clinical regulatory landscape evolving across the UK and EU, should we be making the UK the go to place for Phase I clinical studies?